EMIS post-mortem:
One reason I’m interested in EMIS’ oral-insulin data is to see whether portal delivery of insulin is really an advantage vs systemic delivery, as EMIS and at least one other company have asserted. Alas, the data released today are too sketchy to say much of anything on this score.
It’s simply preposterous, IMO, that EMIS labeled the mean HbA1c reduction in each trial arm as supplementary data to be released after further study rather than top-line data to be released immediately.
Market Data 
Markets 
AI
